Thomas Bures's most recent trade in Bruker Corp was a trade of 500 Common Stock done at an average price of $47.4 . Disclosure was reported to the exchange on March 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bruker Corp | Thomas Bures | Chief Accounting Officer | Purchase of securities on an exchange or from another person at price $ 47.40 per share. | 10 Mar 2025 | 500 | 3,472 (0%) | 0% | 47.4 | 23,698 | Common Stock |
| Bruker Corp | Thomas Bures | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 2,972 | 2,972 (0%) | 0% | 0 | Common Stock | |
| Pieris Pharmaceuticals Inc | Thomas Bures | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 249,080 | 249,080 | - | - | Stock Option (right to buy) | |
| Pieris Pharmaceuticals Inc | Thomas Bures | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 215,819 | 215,819 | - | - | Stock Options (Right to buy) | |
| Pieris Pharmaceuticals Inc | Thomas Bures | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 150,000 | 150,000 | - | - | Stock Options (Right to buy) |